Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- First Posted Date
- 2004-02-20
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 587
- Registration Number
- NCT00003299
- Locations
- 🇺🇸
CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
🇺🇸CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States
Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma
- First Posted Date
- 2004-02-20
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 53
- Registration Number
- NCT00003573
- Locations
- 🇺🇸
Hope Children's Hospital, Oak Lawn, Illinois, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Saint Jude Midwest Affiliate, Peoria, Illinois, United States
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005791
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00017459
- Locations
- 🇺🇸
University of Florida Health Science Center - Jacksonville, Jacksonville, Florida, United States
🇺🇸Los Angeles County Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸John Wayne Cancer Institute, Santa Monica, California, United States
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 36
- Registration Number
- NCT00003582
- Locations
- 🇺🇸
Sylvester Cancer Center, University of Miami, Miami, Florida, United States
3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
- Conditions
- Interventions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT00077545
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery
- Conditions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00004003
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
- Conditions
- Interventions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00004919
- Locations
- 🇺🇸
COG Phase I Consortium, Arcadia, California, United States
Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach Cancer
- Conditions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00006038
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma
- Conditions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- University of Leicester
- Target Recruit Count
- 57
- Registration Number
- NCT00077389
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom
🇬🇧Middlesex Hospital, London, England, United Kingdom
🇬🇧Children's Cancer and Leukaemia Group, Leicester, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.